UK reverses reimbursement decision on Eisai's kidney cancer therapy
Related Biotechnology, Pharmaceutical and Healthcare News
In a reversal of its earlier draft decision, the UK’s health technology assessor has provided final…
Original Article: UK reverses reimbursement decision on Eisai's kidney cancer therapy
NEXT ARTICLE
More From BioPortfolio on "UK reverses reimbursement decision on Eisai's kidney cancer therapy"